Evidence map›Paper›PMID 34561784›Full record

ArticleEndocrine2022

Jörn-Markus Gass, Corinna Wicke, Caroline Mona, Klaus Strobel, Werner Müller, Jürg Metzger, Isabelle Suter-Widmer, Christoph Henzen, Stefan Fischli

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Article
  3. Use of [European journal of nuclear medicine and molecular imaging · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jörn-Markus Gass *Division of Visceral Surgery, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Corinna Wicke *Thyroid Center, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Caroline MonaDivision of Endocrinology, Diabetes and Clinical Nutrition, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Klaus StrobelThyroid Center, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Werner MüllerThyroid Center, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Jürg MetzgerDivision of Visceral Surgery, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Isabelle Suter-WidmerDivision of Endocrinology, Diabetes and Clinical Nutrition, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Christoph HenzenThyroid Center, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland.
Stefan FischliThyroid Center, Luzerner Kantonsspital, 6000, Luzern 16, Switzerland. stefan.fischli@luks.ch.ORCID http://orcid.org/0000-0003-1659-343X
Luzerner Kantonsspital · CHUniversity of Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHyperparathyroidism (HPT) is a common disorder. A cure can only be achieved by removing all diseased glands. It is critical to localize the hyperfunctioning glands exactly to prevent extensive surgical exploration. The number of false negative/inconclusive results in standard imaging techniques is high. We aimed to evaluate the diagnostic accuracy of

methodsA total of 96 patients with HPT and negative/equivocal conventional imaging were referred for FCH-PET/CT. In this retrospective, single institution study, 69 patients, who have undergone surgery and histopathologic workup, were analyzed. Of the 69 patients included, 60 patients suffered from primary HPT, four from secondary or tertiary HPT, and five from familial HPT. Sensitivities, positive predictive values, and accuracies were calculated.

resultsSensitivity/positive predictive value (PPV) per lesion was 87.5/98.3% for primary HPT, 75/100% for secondary/tertiary HPT and 25/66.7% for familial HPT. Sensitivity/PPV per patient was 91.5/98.2% for primary HPT, 100/100% for secondary/tertiary HPT and 50/100% for familial HPT. All patients showed normalized serum calcium levels in the postoperative period. The follow-up rate was 97%. Of the patients included in the study, 58 of 60 patients with primary HPT, and four of four patients with secondary/tertiary HPT showed normal calcium and parathyroid hormone (PTH) levels after six months and were cured. Of the patients with familial HPT, four of five patients were cured.

conclusionDiagnostic accuracy of

Indexed as

Hyperparathyroidism, PrimaryParathyroid GlandsCholineHumansPositron Emission Tomography Computed TomographyRetrospective StudiesTechnetium Tc 99m SestamibiCholinefluorocholineTechnetium Tc 99m Sestamibi18F-Fluorocholine-PET/CTEndocrine surgeryHyperparathyroidismParathyroidectomy

Identifiers

PMID34561784
OpenAlexW3201046164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.